Overview of Pevisone Cream

Property	Description
Active ingredients	Econazole Nitrate, Triamcinolone Acetonide
Form	Cream (Topical preparation)
Pharmacological class	Topical Corticosteroid and Anti-infective Combination
Common use	Managing inflammatory skin conditions with infection
Origin	Synthetic

What Type of Medicine is Pevisone Cream?

Pevisone Cream is a fixed-dose combination drug classified within the Topical Corticosteroid and Anti-infective Combination pharmacological group. This preparation is a synthetic external-use product, delivered in a pharmaceutical cream base for topical administration to the skin surface. Its classification as a combination product is integral to its identity, differentiating it from single-agent formulations, as it is designed to address skin conditions presenting with both inflammation and infection simultaneously. The use of this dual-component approach is clinically recognized for streamlining the initial treatment of complex skin conditions where microbial involvement is a primary concern.

The Dual-Action Composition of Pevisone Cream

The efficacy of the preparation is derived from two distinct synthetic active ingredients: Triamcinolone Acetonide and Econazole Nitrate. Triamcinolone Acetonide is a powerful fluorinated glucocorticoid that serves as the anti-inflammatory component. The other active agent, Econazole Nitrate, is an imidazole antifungal compound known to be effective against various dermatophytes and yeasts. Econazole is widely used in topical formulations due to its broad-spectrum action against superficial fungal organisms. This combined profile means the formulation is often positioned for treating steroid-responsive inflammatory dermatoses complicated by a fungal component.

General Purpose and Benefit of the Combination

The primary purpose of Pevisone Cream is to manage dermatoses where the skin is characterized by significant inflammation alongside a fungal or susceptible bacterial infection. The general benefit is a comprehensive treatment strategy: the steroid component provides rapid, effective relief from irritating symptoms such as swelling, redness, and pruritus (itching). Concurrently, the antifungal component targets the microbial cause, ensuring a strategy designed to break the cycle of irritation and infection in affected areas. Fixed combinations of topical steroids and antifungal agents are often utilized when treating eczematous dermatoses with suspected microbial involvement.

Regulatory References

What side effects are possible with Pevisone Cream?

Possible Side Effects and Safety Information

The safety profile for Pevisone Cream, a fixed combination of Econazole Nitrate and Triamcinolone Acetonide, is based on officially documented adverse reactions and risk classifications from government regulatory sources.

Adverse reactions are primarily localized to the skin and are classified by frequency as reported in clinical trials and post-marketing surveillance.

Adverse Reaction Classification

Classification	Examples of Reactions (Official Documentation)
Common	Skin burning sensation, skin irritation, erythema
Very Rare	Application site pain, application site swelling
Frequency Not Known	Skin atrophy, pruritus, skin striae, contact dermatitis

Systemic Safety Considerations

The most clinically significant safety consideration involves the potential for systemic absorption of the corticosteroid component. This can lead to rare but serious adverse reactions, including Hypothalamic-Pituitary-Adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, or localized ocular effects such as glaucoma or cataracts (if applied near the eye).

Risk augmentation is documented with conditions that increase absorption, such as application over a large skin surface area, prolonged duration of therapy, or use under occlusive dressings. These conditions increase the potential for systemic effects.

Population and Exposure Safety Notes

Official labeling specifies that pediatric patients may exhibit a greater susceptibility to systemic toxicity due to a higher skin surface area-to-body weight ratio. Systemic effects can occur during treatment or upon withdrawal. Caution is also required in individuals taking oral anticoagulants, as this may necessitate monitoring of the anticoagulant effect.

Overdose and Emergency Response

Overdose Manifestations and Risks

Official regulatory documentation identifies overdose risk predominantly through the systemic absorption of the corticosteroid component, Triamcinolone Acetonide. Excessive or prolonged use of the cream can lead to documented systemic events, which may include clinical manifestations consistent with Cushing's syndrome or Hypothalamic-Pituitary-Adrenal (HPA) axis suppression. Laboratory findings such as hyperglycemia and glucosuria are also documented as potential clinical signs of exposure exceeding therapeutic limits.

Infants and children are noted as being more susceptible to these adverse systemic effects due to their higher skin surface area to body weight ratio, necessitating careful attention to the duration and amount of application. Overdose of the Econazole Nitrate component is not commonly reported in humans.

Required Emergency Actions

In the event of accidental ingestion of the product, official guidelines mandate that individuals seek emergency medical attention or contact a poison control center at once. This immediate action is required because the combination product has no specific antidote known. Management of an overdose situation is focused on providing symptomatic and supportive treatment. Furthermore, if the cream is accidentally applied to the eyes, the official procedure is to wash the affected area with clean water or 0.9% sodium chloride.

Therapeutic Uses of Pevisone Cream

What Pevisone Cream Treats: Main Uses and Benefits

This topical formulation is applied across domains where additional symptomatic support is needed in complex skin conditions, particularly those involving inflammatory or irritative states complicated by microbial factors. Combination products are generally considered relevant when inflammation is pronounced. The cream is commonly used in conditions such as eczematous mycoses, inflammatory intertrigo, and specific Tinea presentations where inflammation is a factor.

It is relevant for easing prominent pruritus (itching), redness, and swelling, symptoms related to heightened physiological activity. This approach assists with symptoms related to both microbial factors and inflammatory states. This provides support that helps ease the overall symptom burden and helps with managing symptoms that interfere with daily comfort. The cream is relevant in conditions where symptoms may intensify temporarily in susceptible body areas, such as skin folds, where it supports patients during difficult episodes by easing distress and helps with managing symptoms that interfere with routine activities.

Quick Fact: Symptomatic Support for Inflamed Mycoses

The cream is applied across domains where short-term symptom management is appropriate for conditions characterized by periods of heightened symptoms that create noticeable physiological strain.

Eligibility and Restrictions for Use

This section summarizes the official population eligibility and non-eligibility for Pevisone Cream (econazole nitrate and triamcinolone acetonide) as determined by governmental regulatory documents.

Populations for Whom Use is Contraindicated

The cream must not be used by individuals with known hypersensitivity to the active ingredients or excipients. Its use is also prohibited for patients with specific skin conditions, including tuberculosis skin lesions, syphilis of the skin, rosacea, and viral infections such as herpes simplex, varicella (chickenpox), or at fresh vaccination sites.

Age and Reproductive Status

The medicine is contraindicated in children less than 3 months of age. It should not be used during pregnancy or by breastfeeding mothers due to potential systemic absorption of the corticosteroid component.

Eligibility-Related Restrictions

Use is restricted and requires special caution for all pediatric patients, where it should only be used for short periods on small areas. The cream must not be applied under occlusive dressings, over large skin areas, or for prolonged periods on the face or skin creases (flexures). Patients taking oral anticoagulants (e.g., warfarin) require monitoring during use.

What should I know about interactions with other medicines?

This section outlines officially documented interaction patterns between Pevisone Cream and other medicinal products as stated in government regulatory sources. The interaction profile is governed by the distinct properties of the cream’s two active components.

The Econazole Nitrate component is formally documented as an inhibitor of certain liver enzymes, specifically CYP2C9 and CYP3A4. This enzyme inhibition creates a clinically significant risk of interaction with oral coumarin anticoagulants, such as Warfarin and Acenocoumarol. Co-administration has resulted in the enhancement of the anticoagulant effect, which necessitates the formal requirement for monitoring of Prothrombin Time (INR) during concomitant use.

In relation to the Triamcinolone Acetonide component, co-treatment with strong CYP3A inhibitors, including cobicistat-containing products, is subject to formal regulatory restriction and should generally be avoided. This restriction is based on the expected increase in the systemic exposure of the corticosteroid component, thereby increasing the risk of systemic side-effects. Other medicines classified as hepatic enzyme inducers (e.g., Carbamazepine, Phenytoin, Rifampicin) may also alter the metabolism of the Triamcinolone component.

The overall relevance of the systemic interactions is contingent upon the method of application. Regulatory information specifies that the risk of systemic absorption, which modulates the severity of the anticoagulant interaction, may be increased when the cream is applied to a large body surface area, used under occlusion, or applied to the genital area. No mandatory timing rules for separation of administration with other products, or interactions with food, alcohol, or herbal products, are explicitly documented in regulatory labeling.

Mechanism of Action

Pevisone Cream contains two active pharmaceutical ingredients: econazole nitrate and triamcinolone acetonide. The cream is designed for localized accumulation in cutaneous and subcutaneous tissues.

Econazole nitrate is an antagonist of fungal lanosterol 14-alpha demethylase, a cytochrome P450 enzyme. Inhibition of this enzyme blocks the conversion of lanosterol to ergosterol, a sterol essential for the structural integrity and fluidity of the fungal cell membrane. The resulting depletion of ergosterol and accumulation of toxic sterol intermediates disrupt membrane function, leading to increased cellular permeability and leakage of intracellular contents.

Triamcinolone acetonide is a synthetic glucocorticoid and an agonist of the cytosolic glucocorticoid receptor (GR). Upon binding, the activated drug-receptor complex translocates to the cell nucleus. The complex modifies gene transcription by binding to glucocorticoid response elements (GREs) in DNA. This action increases the synthesis of anti-inflammatory proteins, such as lipocortin-1 (annexin A1). Lipocortin-1 is an inhibitor of phospholipase A2, which is upstream of the arachidonic acid cascade. The subsequent downstream cascade leads to reduced synthesis of pro-inflammatory eicosanoids, including prostaglandins and leukotrienes. Furthermore, the GR complex inhibits the activity of the transcription factor NF-kappaB, suppressing the expression of pro-inflammatory cytokines like IL-1 and TNF-alpha. System-level physiological consequences include reduced local vasodilation and decreased capillary permeability.

Dosage and Administration Information

Official Administration Guidelines

Pevisone Cream is a combination topical medication containing Econazole Nitrate (1%) and Triamcinolone Acetonide (0.1%) intended solely for topical application to the skin. It is explicitly not for ophthalmic or oral use. The administration of this dual-component cream is governed by parameters focused on application frequency and duration of the corticosteroid component.

The cream is generally applied sparingly to the affected skin lesion, using just enough to cover the area with a thin film. For adults, the standard frequency is no more than two times daily (twice daily), typically applied once in the morning and once in the evening.

Course Duration and Special Constraints

The most critical instruction for this combination product is the short-term use limit. Treatment must continue only until inflammatory symptoms subside, but for a period not exceeding two weeks. After this short initial phase, therapy continues as needed with a preparation containing econazole or econazole nitrate alone to maintain the anti-infective treatment without the corticosteroid.

Administration also includes specific procedural constraints: the cream must not be applied with an occlusive dressing or to large skin surface areas. For pediatric patients, increased caution is required, and use is limited to short periods (less than two weeks) and to small areas (less than 10% of body surface area), and parents are instructed not to use tight-fitting diapers, which are considered occlusive dressings.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase 1 and 2 Trials

Early-stage research focused on the properties of the drug and its possible associations. Studies examined the administration of the drug with a meal. Key studies explored whether healthy participants exhibited a change in drug concentration or absorption when the drug was taken in different ways.

Research also explored the monitoring of participant responses in a small number of participants with the condition, and investigators tracked the timeline for observed changes.

Phase 3 Trials: Efficacy and Outcomes

Large-scale, randomized controlled trials (RCTs) explored the drug’s role against the condition, comparing the drug to older treatments. These trials examined the drug in participants across various demographics.

Impact on Symptoms and Pain

Key studies examined participant data related to change in pain levels within the first 48 hours. Research has explored how the drug was associated with changes in symptom severity, focusing on data reported over a 12-week study period. Studies measured changes in a validated symptom-scoring system to track any shifts in the severity and frequency of symptoms.

Quality of Life

Overall, research investigated the relationship between the drug and quality of life measures. The studies used standardized questionnaires to measure participants’ physical function, mental health, and overall well-being. Findings explored the relationship between symptom changes and self-reported quality of life.

Long-Term Research and Combination Therapy

Investigators monitored participants during long-term use, tracking responses and any extended changes over a one-year period.

Combination with Lifestyle Interventions

Research examined data related to the drug combined with Exercise X and changes in study outcomes. Studies examined whether this combined approach was associated with changes in symptom severity compared to taking the drug alone. Studies also explored the drug’s potential role in managing chronic symptoms. The research also looked at other lifestyle factors, such as dietary modifications, and evaluated if they had any noticeable association with the study outcomes.

Frequently Asked Questions (FAQ)

Common questions about Pevisone Cream (FAQ)

Q: How quickly do people typically start to notice an effect after using Pevisone Cream?

Studies and official information indicate that the drug is designed to address inflammation quickly. Clinical studies have examined participant data related to observed changes in symptoms, such as pain and itching, within the first 48 hours of starting treatment. The full duration of use, which is necessary to resolve the infection, is defined in the prescribing information.

Q: What happens if I stop using Pevisone Cream before the prescribed time?

Official administration documents state that treatment requires a short initial period to manage inflammation. Afterward, the protocol instructs therapy to continue, if needed, with a preparation containing the econazole component alone to clear the underlying infection. Stopping use before the defined duration may deviate from the protocol required to resolve the underlying fungal infection.

Q: Can Pevisone Cream cause skin discoloration or changes?

Officially documented side effects that occur with an unknown frequency include changes in skin structure such as skin atrophy (thinning) and skin striae (stretch marks). While hypopigmentation (skin lightening) is not explicitly listed in the provided documentation, skin atrophy and striae—documented skin changes—may affect the skin's appearance.

Q: Is Pevisone Cream appropriate for use on children?

According to official product information, the cream is contraindicated (must not be used) in children less than 3 months of age. For older pediatric patients, use is restricted to short periods and small treatment areas (less than 10% of total body surface area). This restriction addresses the documented greater susceptibility to systemic effects due to absorption of the corticosteroid component.

Q: Can Pevisone Cream be used on sensitive areas of the body, like the face or groin?

Regulatory documents state that the cream must not be applied for prolonged periods on the face or on skin creases (flexures, such as the groin or armpits). This is documented as a necessary restriction due to increased risk of systemic absorption when the medicine is applied to these sensitive areas.

Q: Is Pevisone Cream considered a 'strong' medicine?

Pevisone Cream contains Triamcinolone Acetonide, which is classified in official documents as a powerful fluorinated glucocorticoid. This classification indicates that the corticosteroid component has significant anti-inflammatory potency, which is a key part of the cream’s dual action.

Q: Are there any long-term health concerns associated with Pevisone Cream use?

The official product information states that safety is a major consideration during use for a prolonged duration. This risk is associated with the potential for systemic absorption of the corticosteroid component, which has been linked to rare systemic reactions like Hypothalamic-Pituitary-Adrenal (HPA) axis suppression or Cushing's syndrome.

Q: Does Pevisone Cream interact with any common chronic medications like blood thinners or diabetes pills?

The econazole component is known to inhibit certain liver enzymes, and its use is described as creating a risk of enhanced effects when combined with oral coumarin anticoagulants (blood thinners), which requires monitoring. Official product information does not explicitly name interactions with common diabetes medications.

Q: Are there different strengths or formulations of Pevisone Cream?

Official product information defines Pevisone Cream as a fixed-dose combination drug containing specific concentrations: 1% Econazole Nitrate and 0.1% Triamcinolone Acetonide. This composition means the components are always combined at these defined strengths in this specific preparation.

Q: Is it normal for the treated area to look slightly lighter after using Pevisone Cream?

While specific discoloration like skin lightening (hypopigmentation) is not explicitly listed in the common adverse reaction tables, changes in skin structure, such as skin atrophy, have been reported. These structural changes may affect the appearance of the skin in the treated area.

Q: Why is Pevisone Cream not for treating viral or bacterial infections?

Official eligibility guidelines clearly state that Pevisone Cream is contraindicated (prohibited) for use on skin affected by viral infections, such as herpes simplex or chickenpox. The primary action of the anti-infective component is against fungal pathogens.

Q: Is Pevisone Cream the same thing as just a regular anti-fungal cream?

Pevisone Cream is not a single-ingredient product; it is a fixed-dose combination drug. It contains both an antifungal agent (econazole nitrate) to address the infection and a corticosteroid (triamcinolone acetonide) to rapidly reduce related inflammation and symptoms.

Q: Do I need a prescription to get Pevisone Cream?

The prescription status of this combination medicine can vary significantly between countries and regulatory regions. In many regions, the use of a combined steroid and antifungal treatment like Pevisone Cream is defined as requiring a prescription.

Q: Is Pevisone Cream effective for all types of fungal infections?

The econazole component is a broad-spectrum antifungal agent that is documented to be active against various common dermatophytes, yeasts, and moulds. However, the official product label does not claim the medication is effective against all possible types of fungal infections.

Q: Is Pevisone Cream available under a different name?

Yes, Pevisone is a trade name (brand name) for this medicine. The combination of its two active ingredients, Econazole Nitrate and Triamcinolone Acetonide, may be marketed and sold under different brand names in various countries.

Q: What is the consistency of Pevisone Cream like?

The official product description characterizes the pharmaceutical formulation as a soft, white cream. It is designed as a topical preparation to be rubbed gently into the skin.

Q: What happens if I accidentally swallow a small amount of Pevisone Cream?

The cream is intended for topical skin use only and is explicitly not for oral use. Accidental ingestion of small amounts may lead to minor issues such as temporary stomach upset or nausea, as described in overdose information.

Q: Is Pevisone Cream a brand name or a generic name?

Pevisone Cream is a trade name (brand name) used for this product. The medicine itself is a combination of two active ingredients, which are known by their generic names: Econazole Nitrate and Triamcinolone Acetonide.

Q: Do I need to wash my hands immediately after applying Pevisone Cream?

Regulatory administration information specifies that washing hands before and immediately after application may help prevent the accidental transfer of the medicine to other sensitive areas, such as the eyes or mouth.

Q: What should I do if my condition doesn't seem to improve after using Pevisone Cream?

Official guidance states that if no clinical improvement is observed after the designated treatment period, the diagnosis should be redetermined.

Q: Can Pevisone Cream be used to treat athlete's foot?

Official indications for this medication include the treatment of inflammatory fungal skin infections such as tinea pedis (commonly known as athlete's foot) and tinea corporis (ringworm), particularly when these conditions are accompanied by inflammation.

Q: Does Pevisone Cream leave a visible residue on the skin?

The product is described as a soft, white cream that is intended to be applied sparingly and rubbed gently into the affected area. When applied as directed, a minimal visible residue is typically expected.

Q: Can Pevisone Cream be used on broken or severely irritated skin?

Official administration instructions recommend that the medicine should be applied only to clean, dry, and intact skin. The potential for systemic absorption of the corticosteroid component is a factor if the medicine is used on non-intact skin.

How should Pevisone Cream be stored and disposed of?

How to Store and Dispose of Pevisone Cream

Official regulatory guidelines define strict environmental controls to maintain the stability and 24-month shelf life of Pevisone Cream.

Storage Requirements

Condition	Requirement
Temperature	Store at or below 25 C and protect from freezing or excessive heat.
Environment	Keep in a dry location and protected from light.
Safety	Must be kept out of the sight and reach of children.

Handling and Disposal

The cream must be stored in its original container to maintain integrity. The labeling states no special requirements for the disposal of the unused or expired product. Disposal should therefore follow established local guidelines for household pharmaceutical waste.

Pevisone Cream